At the end of the inspection, no observation (483) is issued.
The US Food and Drug Administration (USFDA) inspected the company's formulations manufacturing facility located at Baddi (Himachal Pradesh) from 2nd to 9th March 2020. This was a Current Good Manufacturing Practice (cGMP) and post approval inspection. At the end of the inspection, no observation (483) is issued, the company said in a statement on Monday, 9 March 2020.Cadila Healthcare is a pharmaceutical company based in India. On a consolidated basis, the drug maker's net profit fell 26.5% to Rs 375.18 crore on a 0.5% increase in net sales to Rs 3,534.50 crore in Q3 December 2019 Q3 December 2018.
Shares of Cadila Healthcare were down 3.38% at Rs 257.20. Meanwhile, the benchmark BSE Sensex tanked 1830.65 points or 4.87% to 35,745.97 amid global selloff.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
